Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride lowers blood glucose primarily by inhibiting hepatic gluconeogenesis, thereby decreasing the amount of glucose released into the bloodstream. It also improves peripheral insulin sensitivity, facilitating greater glucose uptake by muscle and adipose tissue. These actions occur without stimulating insulin release, reducing the risk of hypoglycaemia when used alone.

The appropriate dose of Jansitin Duo is individualized by the prescribing healthcare professional based on factors such as renal function, current glycaemic control, and concomitant medications. The prescriber will determine the tablet strength, frequency, and any titration schedule needed to achieve therapeutic goals while minimizing adverse effects.

Safety of Jansitin Duo in pregnancy and lactation has not been fully established. Metformin is sometimes continued during pregnancy under specialist supervision, whereas sitagliptin lacks sufficient data. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician before using this medication.

To place an order, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity of Jansitin Duo. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Jansitin Duo offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitising and incretin‑enhancing effects in a single tablet. Compared with metformin alone, it delivers additional glucose‑lowering potency without the need for separate DPP‑4 inhibitor prescriptions. Relative to other combination products, its safety profile aligns with the known tolerability of its individual components.

Store Jansitin Duo tablets at ambient temperature below 25 °C (77 °F). Keep the product in its original blister pack or container, protect it from moisture, excessive heat, and direct sunlight. Do not store in the refrigerator or freezer, and keep out of reach of children.

Jansitin Duo is taken orally, usually with a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush, split, or chew the tablet unless specifically instructed.

The most serious risks include metformin‑associated lactic acidosis, which is rare but potentially fatal, and sitagliptin‑related acute pancreatitis. Severe hypersensitivity reactions such as anaphylaxis may also occur. Patients should be educated to seek immediate medical attention for symptoms like unexplained muscle pain, rapid breathing, severe abdominal pain, or signs of an allergic reaction.

Jansitin Duo is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease, uncontrolled heart failure, or a history of pancreatitis.